Viridian's 15-minute chart sees KDJ Golden Cross, bullish Marubozu pattern.

The 15-minute chart for Viridian has recently triggered a Golden Cross, along with a Bullish Marubozu at 08/11/2025 12:00. This indicates a shift in the momentum of the stock price towards a more positive direction, suggesting that the stock has the potential to continue increasing in value. The dominance of buyers in the market is evident, and it is likely that the bullish momentum will persist.

Viridian Therapeutics, Inc. (VRDN) has shown signs of a significant shift in its stock price momentum with the recent occurrence of a Golden Cross and a Bullish Marubozu on the 15-minute chart, as of August 11, 2025, at 12:00. This technical indicator suggests a potential upward trend in the stock's value, with buyers dominating the market. The company's earnings report for the second quarter (Q2) 2025, released on July 2, 2025, further highlights its strategic advances and strong cash position [1].

Earnings Highlights

Viridian reported a 4.2% increase in revenue to $75,000, exceeding market estimates [1]. Despite a 55% widening in net losses to $100.73 million, the company's strong cash position of $563.4 million as of June 30, 2025, positions it competitively in the biotechnology industry [1]. The company's flagship product, Veligrotug, received Breakthrough Therapy Designation (BTD) from the FDA and an exclusive license agreement with Kissei Pharmaceutical for global promotion [1].

Analyst Views

Analysts have mixed views on Viridian's prospects. Oppenheimer analyst Leland Gershell raised the target price for Viridian to $32.00 from $28.00, maintaining an 'Outperform' rating [2]. The average target price from 16 analysts is $38.75, indicating a 129.15% upside from the current price [2]. Goldman Sachs analyst Richard Law maintained a 'Buy' rating and raised the price target to $30.00 [3]. RBC Capital analyst Lisa Walter lowered the price target to $41.00, while Wells Fargo analyst Derek Archila maintained an 'Equal-Weight' rating and lowered the price target to $26.00 [3].

Investment Outlook

Investors should closely monitor Viridian's earnings outlook and regulatory milestones, as these factors could significantly impact the company's stock price. The company's earnings call will provide further insights into its financial health and future prospects. The stock's valuation remains mixed, with a high Price-to-Sales (P/S) ratio and a reasonable Price-to-Book (P/B) ratio [1].

References

[1] https://www.ainvest.com/news/viridian-2025-q2-earnings-wider-losses-regulatory-partnership-momentum-2508/
[2] https://www.ainvest.com/news/oppenheimer-boosts-viridian-therapeutics-target-price-32-00-maintaining-outperform-rating-2508/
[3] https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/46976231/these-analysts-revise-their-forecasts-on-viridian-therapeutics-following-q2-results